Compare Marathon Digital Holdings Inc (MARA) vs ResMed Inc. (RMD) Price & Performance

Marathon Digital Holdings (MARA) trades at $9.95, up 4.08% today but remains under pressure with a bearish technical signal. The company reported a Q2 2026 net loss of $1.60 per share, missing estimates, as revenue fell to $804 million with a net income margin of -429.71%. Despite negative cash flow from operations, MARA is pivoting toward AI digital infrastructure, appointing new directors to support growth. Analyst consensus is mixed with a $16.08 price target but high volatility persists.

MARA's outlook is challenged by persistent losses and high execution risk in its strategic shift, though its low P/E of 3.37 suggests deep value if the AI pivot succeeds. Key risks include Bitcoin price sensitivity, competitive pressures, and cash burn. Investors should weigh the 50% buy rating against fundamental weaknesses before considering a position.

ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.

The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.